Recent Health Resources and Services Administration (HRSA) audits found that two drugmakers overcharged covered entities for their 340B drugs, fueling [...] …
Blog Posts
SPONSORED CONTENT
The purpose of the 340B drug pricing program remains a contested question between 340B providers and some in the pharmaceutical industry. In addition, there are questions regarding 340B’s scope including the contract pharmacy program and the definition of patient.
…
Two influential players in the 340B world have recently taken on key positions at retail pharmacy giant Walgreens, one of [...] …
State legislators in California, Texas and Oklahoma have recently advanced 340B contract pharmacy access bills with amendments that in some [...] …
A Japanese pharmaceutical giant and Massachusetts biotechnology company recently announced changes to their respective 340B contract pharmacy restrictions. Tokyo-based Takeda [...] …
News Alert
Stakeholders React to HELP Committee Chair Cassidy’s 340B Probe Findings, Reform Recommendations
340B hospitals, contract pharmacies, health center advocates and the drug industry offered mixed responses Thursday on the long-awaited findings and [...] …
The leader of a key U.S. Senate Committee tasked with overseeing the 340B program called Thursday for Congress to improve [...] …
While much of the focus in Washington, D.C. has been on confirmation hearings and budget matters, the 340B program continued [...] …
Indiana lawmakers yesterday overwhelmingly approved a bill that would require state hospitals to annually report extensive financial and operational information [...] …
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …